The manufacturer of brand-name Focalin XR (dexmethylphenidate extended-release) capsules has discontinued production. Illinois Medicaid has designated generic dexmethylphenidate ER capsules as preferred while continuing to list brand-name Focalin XR as preferred on the PDL until inventory is depleted. This change applies to both Fee-For-Service and Managed Care Organizations effective July 24, 2026.
Get alerts when payers change rules like this one
We check Illinois Medicaid - HFS and other payers every day and email you when a change matches your specialty and state.
01Billing and pharmacy teams should monitor prescription claims for Focalin XR brand-name to identify when patients transition to generic dexmethylphenidate ER.
02Update internal records and patient communication templates to reflect the preferred status of generic dexmethylphenidate ER.
03Coordinate with prescribing providers (physicians and APRNs) to encourage generic substitution for new prescriptions.
04No immediate billing code changes required, but ensure claims processing systems are prepared to accept both brand-name (while inventory lasts) and generic formulations without denial.
05Contact the Bureau of Professional and Ancillary Services at 877-782-5565 with coverage questions.
Original notice
PDL Update to Brand-name Focalin XR Capsules
hfs.illinois.gov · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.